Pharma BD Deal Intelligence

Sun Pharmaceutical Industries Limited / Organon & Co.

2026 · Acquisition/Merger · $11.8B · Pending

Announcement Sentiment

Strongly positive

Sun Pharma agreed to acquire Organon & Co. for $14.00 per share in an all-cash transaction with an enterprise value of $11.75B, expanding Sun Pharma into Top-10 global biosimilars and a top-3 global women's health franchise.

Key facts

Announced Apr 27, 2026
Deal value $11.8B
Deal type Acquisition/Merger
Therapeutic area women's health and general medicines (biosimilars)
Indications women's health and general medicines (biosimilars)
Key assets Organon women's health and biosimilars portfolio (70+ products including Nexplanon, Jada, biosimilars including Hadlima/Renflexis/Brenzys/Ontruzant)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals